

FY24 Q1 earnings results



The **U.S. Healthcare** segment had first quarter sales of **\$1.9B** with **+12%** pro forma growth, led by VillageMD and Shields

International segment Q1 sales: **\$5.8B**, up **12.4%** from year-ago quarter



“WBA delivered fiscal first quarter results in line with overall expectations, reflecting disciplined execution in a challenging consumer backdrop. We are evaluating all strategic options to drive sustainable long-term shareholder value, focusing on swift actions to right-size costs and increase cash flow, with a balanced approach to capital allocation priorities. Today we are announcing a 48 percent reduction in our quarterly dividend payment, while maintaining a competitive yield. We are proud to be a trusted and independent partner of choice, delivering healthcare to millions of people. And, we will leverage our local, convenient presence to engage with patients and help payors, providers, and pharma companies also achieve better health outcomes at an affordable cost.”

Tim Wentworth, Chief Executive Officer

Building on our core pharmacy strength and our trusted brand to evolve healthcare and customer experience



Leveraging our local presence to engage with patients across our thousands of stores and through our assets across the care continuum



Enabling pharmacists to spend less time on routine tasks and more time on meaningful interactions and providing essential care



Redefining what we can do to help payors, providers, and pharma achieve better health outcomes at an affordable cost



Building on our established assets in a capital efficient way, to expand services, and support patients and partners



Becoming the independent partner of choice in healthcare services

FY24 Outlook:

Good execution against a challenging consumer backdrop

Full-year 2024 adjusted EPS guidance maintained at \$3.20-\$3.50

On pace toward \$1B in cost savings

U.S. Healthcare adjusted EBITDA expected to be breakeven at midpoint of the guidance range of **(\$50M) to \$50M**

For complete results, announced on January 4, 2024, please [click here](#).

This message contains selected results from WBA's fiscal quarter ended November 30, 2023, and is not intended to be a substitute for a comprehensive review of the company's earnings release, linked above and available in the Investor Relations section of walgreensbootsalliance.com, and the company's filings with the U.S. Securities and Exchange Commission, which can be found at www.SEC.gov. Cautionary Note Regarding Forward-Looking Statements: All statements in this message that are not historical are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, known or unknown, that could cause actual results to vary materially and speak only as of the date they are made. The company does not undertake, and expressly disclaims, any duty or obligation to update publicly any forward-looking statement after the date of this message. WBA reports earnings according to generally accepted accounting principles (GAAP). The company's adjusted results are non-GAAP financial measures that exclude the impact of certain items affecting comparability and that supplement GAAP results. Please refer to the "Supplemental Information (Unaudited) Regarding Non-GAAP Financial Measures" in the press release for more information, including reconciliations to the most directly comparable GAAP financial measures.